Printer Friendly

EMPYREAN DIAGNOSTICS INC., SUBSIDIARY OF SOCAL CAPITAL CORP., ANNOUNCES RESULTS FROM PHASE-2 CLINICAL TRIALS

 MOUNTAIN VIEW, Calif., April 30 /PRNewswire/ -- Empyrean Diagnostics Inc. is pleased to announce the much anticipated results from the phase-2 clinical trials, with specific reference to the performance of the test kit. The trials were conducted at a leading academic medical facility in San Francisco on the company's proprietary HIV-1 diagnostic test-kit and were conducted by the infectious diseases section of that facility. The trials were conducted under generally accepted testing procedures for the diagnostics industry.
 In the opinion of the assistant chief of the infectious disease section, the test results prove that this technology is well suited for mass marketing in developing countries. The test results confirm the EDI HIV-1 test kit is easy to use, requires no instrumentation and can be conducted in less than 7-minutes. He further commented, "The clinical trial confirms that the Empyrean HIV-1 test kit technology is fundamentally sound." Further, the technologist who performed the actual testing, reports that the test-protocol was easy to understand and the test was simple and easy to perform. As per the established clinical-trial protocol, the statistical data from the phase-2 clinical trials are currently being reconfirmed at second independent laboratory.
 Based on these extremely positive findings and combined with the conclusive outcome of phase-1 of the clinical trials, previously announced in a news release dated Feb. 9, 1993, which showed results of 100 percent sensitivity and 100 percent specificity, management is preparing an Investigative New Device (IND) submission to the U.S. Food and Drug Administration (FDA), to be filed within 30-days.
 As expected, this independent validation of the EDI test kit technology, will substantiate to the diagnostic industry that the technology is now ready for marketing. Furthermore, the company intends to finalize its first license-agreement in May 1993 with a major Western European corporation. This license-agreement will generate substantial revenues for the company in fiscal year 1993.
 Empyrean Diagnostics Inc., of Mountain View is a wholly owned subsidiary of SoCal Capital Corp. (Vancouver: SOL) of Vancouver, British Columbia, and has developed a proprietary and patent pending, inexpensive-to-manufacture HIV-1 diagnostic test kit. EDI is now licensing its leading edge product, which has a projected market in excess of US $500 million.
 -0- 4/30/93
 /CONTACT: Empyrean Diagnostics, 604-687-6223, or 800-567-8181/
 (SOL.)


CO: Empyrean Diagnostics Inc.; SoCal Capital Corp. ST: California, British Columbia IN: MTC SU: PDT

JB -- LA013 -- 3199 04/30/93 12:20 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 30, 1993
Words:398
Previous Article:HOME OWNERSHIP WITHIN REACH FOR QUALIFIED RESIDENTS OF CENTRAL FLORIDA
Next Article:MAZDA PRICES ALL-NEW LARGER, MORE POWERFUL 1994 B-SERIES PICKUP TRUCKS
Topics:


Related Articles
SOCAL CAPITAL ANNOUNCES UPDATE ON RESULTS OF PHASE-ONE EXTERNAL CLINICAL EVALUATION TRIALS ON HIV-1 DIAGNOSTIC ASSAY
EMPYREAN DIAGNOSTICS INC. (SUBSIDIARY OF SOCAL CAPITAL CORP.) ANNOUNCES DETAILS OF AGREEMENT WITH RILLDALE LTD.
SOCAL CAPITAL CORP. ANNOUNCES RESULTS OF CLINICAL TRIALS
EMPYREAN DIAGNOSTICS LTD. ANNOUNCES LICENSE AGREEMENT DETAILS
EMPYREAN DIAGNOSTICS LTD. COMPLETES TESTS
EMPYREAN DIAGNOSTICS INC. ANNOUNCES SUBSCRIPTIONS
EMPYREAN DIAGNOSTICS LTD. REPORTS NO MATERIAL CHANGE
Imaging Diagnostic Systems, Inc. Receives $15 Million Equity Line Of Credit

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters